G1 Therapeutics, Inc. (GTHX) News
Filter GTHX News Items
GTHX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GTHX News Highlights
- For GTHX, its 30 day story count is now at 3.
- Over the past 9 days, the trend for GTHX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest GTHX News From Around the Web
Below are the latest news stories about G1 THERAPEUTICS INC that investors may wish to consider to help them evaluate GTHX as an investment opportunity.
Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics IncIn a notable insider transaction, Chief Medical Officer Rajesh Malik has sold a significant number of shares in G1 Therapeutics Inc (NASDAQ:GTHX), a clinical-stage biopharmaceutical company. |
G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%This month, we saw the G1 Therapeutics, Inc. ( NASDAQ:GTHX ) up an impressive 103%. But will that heal all the wounds... |
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved Long-Term Survival with Subsequent Anticancer Therapies - - Improved Long-Term Survival Also Observed in Patients Who Received Prior Trilaciclib with Cytotoxic Therapy and Were Unable to Receive Subsequent Anticancer Therapy - - Data Presented at the 2023 San Antonio Breast Cancer Symposium (SABCS |
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,700 shares of G1’s common stock and 2,300 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to th |
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumRESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer (mTNBC) from the Company’s Phase 2 trial (NCT02978716) will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), held December 5th through 9th in San Ant |
When Will G1 Therapeutics, Inc. (NASDAQ:GTHX) Turn A Profit?With the business potentially at an important milestone, we thought we'd take a closer look at G1 Therapeutics, Inc.'s... |
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call TranscriptG1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript November 1, 2023 G1 Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.35 EPS, expectations were $-0.31. Operator: Good day and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2023 Financial Results Call. At this time, all participants are in a […] |
Q3 2023 G1 Therapeutics Inc Earnings CallQ3 2023 G1 Therapeutics Inc Earnings Call |
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights- Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter - - Confirmed Expectation of Interim Overall Survival (OS) Analysis for Pivotal Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Reiterated Expectation of Initial OS Results from Phase 2 Trial of Trilaciclib in Combination with an Antibody-Drug Conjugate (ADC) in the First Quarter of 2024 - - |
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Multiple Analyses Also Describe Significant Burden of Chemotherapy-Induced Myelosuppression and Impact on Healthcare Resource Utilization in ES-SCLCRESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world evidence indicating that trilaciclib administered prior to platinum-based chemotherapy in patients with extensive-stage small cell lung |